Morgan Stanley
KYTX icon

Morgan Stanley’s Kyverna Therapeutics KYTX Stock Holding History

Morgan Stanley’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.75M Buy
982,307
+5,018
+0.5% +$44.5K ﹤0.01% 3810
2026
Q1 		$8.43M Sell
977,289
-25,206
-3% -$210K ﹤0.01% 3708
2025
Q4 		$9.42M Buy
1,002,495
+828,292
+475% +$6.15M ﹤0.01% 3665
2025
Q3 		$1.05M Sell
174,203
-27,835
-14% -$111K ﹤0.01% 5153
2025
Q2 		$620K Buy
202,038
+67,128
+50% +$166K ﹤0.01% 5362
2025
Q1 		$260K Sell
134,910
-65,684
-33% -$194K ﹤0.01% 5627
2024
Q4 		$750K Buy
200,594
+80,800
+67% +$387K ﹤0.01% 5234
2024
Q3 		$586K Buy
119,794
+511
+0.4% +$3.94K ﹤0.01% 5323
2024
Q2 		$895K Buy
119,283
+79,352
+199% +$1.21M ﹤0.01% 5027
2024
Q1 		$992K Buy
+39,931
New +$1.11M ﹤0.01% 4958

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Morgan Stanley's KYTX Position: Q2 2026 in Review

Morgan Stanley increased its Kyverna Therapeutics (KYTX) stake by 0.51% in Q2 2026, buying an estimated $44.5K and bringing the position to 982,307 shares worth $8.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3810.

Morgan Stanley first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.42M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Morgan Stanley held 982,307 shares of Kyverna Therapeutics worth $8.75M as of Q2 2026.
  • Morgan Stanley bought 5,018 Kyverna Therapeutics shares in Q2 2026, an estimated $44.5K.
  • Kyverna Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3810 holding.
  • Morgan Stanley first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Morgan Stanley's Kyverna Therapeutics position peaked at $9.42M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.